Atrial Fibrillation - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Atrial Fibrillation - Pipeline Review, H2 2016

Atrial Fibrillation - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Atrial Fibrillation - Pipeline Review, H2 2016
Published Aug 10, 2016
97 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Atrial Fibrillation - Pipeline Review, H2 2016, provides an overview of the Atrial Fibrillation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation
- The report reviews pipeline therapeutics for Atrial Fibrillation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Atrial Fibrillation therapeutics and enlists all their major and minor projects
- The report assesses Atrial Fibrillation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Atrial Fibrillation

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and

  
Source:
Document ID
GMDHC8335IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Atrial Fibrillation Overview91
Therapeutics Development102
  Pipeline Products for Atrial Fibrillation Overview101
  Pipeline Products for Atrial Fibrillation Comparative Analysis111
Atrial Fibrillation Therapeutics under Development by Companies121
Atrial Fibrillation Therapeutics under Investigation by Universities/Institutes131
Atrial Fibrillation Pipeline Products Glance143
  Late Stage Products141
  Clinical Stage Products151
  Early Stage Products161
Atrial Fibrillation Products under Development by Companies172
Atrial Fibrillation Products under Investigation by Universities/Institutes191
Atrial Fibrillation Companies Involved in Therapeutics Development2012
  ARCA biopharma, Inc.201
  AstraZeneca Plc211
  Bristol-Myers Squibb Company221
  Cardiome Pharma Corp.231
  Daiichi Sankyo Company, Limited241
  Dong-A Socio Holdings Co. Ltd.251
  Gilead Sciences, Inc.261
  Laboratoires Pierre Fabre SA271
  Nissan Chemical Industries, Ltd.281
  OMEICOS Therapeutics GmbH291
  Otsuka Holdings Co., Ltd.301
  Xention Limited311
Atrial Fibrillation Therapeutics Assessment329
  Assessment by Monotherapy Products321
  Assessment by Target332
  Assessment by Mechanism of Action352
  Assessment by Route of Administration372
  Assessment by Molecule Type392
Drug Profiles4137
  AFC-1 Drug Profile411
  BMS-919373 Drug Profile421
  bucindolol hydrochloride Drug Profile437
  edoxaban tosylate Drug Profile505
  F-373280 Drug Profile551
  flecainide acetate Drug Profile561
  Gene Therapy for Atrial Fibrillation Drug Profile571
  GS-967 Drug Profile581
  NIP-151 Drug Profile592
  OMT-28 Drug Profile611
  OPC-108459 Drug Profile621
  Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation Drug Profile631
  Small Molecule to Block Kv1.5 for Atrial Fibrillation Drug Profile641
  Small Molecules to Block GIRK for Atrial Fibrillation Drug Profile651
  Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation Drug Profile661
  Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure Drug Profile671
  STP-023725 Drug Profile681
  vernakalant hydrochloride Drug Profile694
  XEN-R0702 Drug Profile731
  XEND-0103 Drug Profile742
  XENR-0703 Drug Profile761
  XENR-0706 Drug Profile771
Atrial Fibrillation Dormant Projects785
Atrial Fibrillation Discontinued Products831
Atrial Fibrillation Product Development Milestones8412
  Featured News &Press Releases841
    May 11, 2016: Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study841
    May 02, 2016: New drug more effective in treating atrial fibrillation841
    Mar 31, 2016: Cardiome Announces Publication of Independent Study Comparing BRINAVESS to IBUTILIDE in Patients with Recent-Onset Atrial Fibrillation851
    Mar 24, 2016: Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA(edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session852
    Jan 27, 2016: Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA871
    Jan 13, 2016: Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia871
    Dec 22, 2015: Cardiome Files New Drug Submission Seeking Canadian Approval Of Intravenous Vernakalant871
    Nov 02, 2015: Daiichi Sankyo, Inc. Announces New Subgroup Analyses of Once-Daily SAVAYSA in Patients with Non-Valvular Atrial Fibrillation Will Be Presented at AHA Scientific Sessions 2015881
    Nov 02, 2015: OMEICOS Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation891
    Sep 23, 2015: UK s NICE recommends once-daily LIXIANA (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation892
    Aug 10, 2015: United Kingdom Department of Health Sets BRINAVESS Pricing911
    Jul 24, 2015: Cardiome Partner Eddingpharm to Initiate BRINAVESS Phase I Study in China911
    Jul 09, 2015: New Therapy to Help Heart Rhythm Patients Means Doctors are "Spoilt for Choice"912
    Jun 25, 2015: Daiichi Sankyo s Once-Daily LIXIANA (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE931
    Jun 12, 2015: Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation942
Appendix962
  Methodology961
  Coverage961
  Secondary Research961
  Primary Research961
  Expert Panel Validation961
  Contact Us961
  Disclaimer971

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Atrial Fibrillation - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Atrial-Fibrillation-Pipeline-Review-H2-2016-2088-16343>
  
APA:
Global Markets Direct - Market Research. (2016). Atrial Fibrillation - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Atrial-Fibrillation-Pipeline-Review-H2-2016-2088-16343>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.